Royalty Pharma plc
RPRX · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2017–FY2025
- History
- 9 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Royalty Pharma plc at a glance
In FY2025, Royalty Pharma plc reported revenue of USD 2,378,193 thousands, EBITDA of USD 1,352,712 thousands, EBITDA margin of 56.9%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 2,263,576 | 2,378,193 | |||
| EBITDA | 2,024,905 | 1,352,712 | |||
| EBITDA margin | 89.5% | 56.9% | |||
| ROIC | 41.1% | 20.4% |
The full 9-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas